Aquinnah Pharmaceuticals
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
750 Main St, Cambridge, Massachusetts, 0...Phone Number
(617) 863-3678Website
www.aquinnahpharma.comRevenue
<$5 MillionIndustry
About Aquinnah Pharmaceuticals
Aquinnah Pharmaceuticals is focused on developing innovative small molecule therapeutics for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease. The company leverages its expertise in RNA-binding proteins and biomolecular condensates to create novel drug approaches that aim to halt disease progression. With support from major pharmaceutical companies and numerous grants, Aquinnah is committed to addressing the urgent medical needs of patients facing these debilitating conditions. Their pioneering research and drug development strategies position them as a leader in the fight against neurodegenerative diseases.Explore more
Aquinnah Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Aquinnah Pharmaceuticals
Compare insights from companies similar to Aquinnah Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Aquinnah Pharmaceuticals Tech Stack
A closer look at the technologies used by Aquinnah Pharmaceuticals
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Aquinnah Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Aquinnah Pharmaceuticals is focused on developing innovative small molecule therapeutics for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease. The company leverages its expertise in RNA-binding proteins and biomolecular condensates to create novel drug approaches that aim to halt disease progressi... Read More
